pyruvic acid has been researched along with Akinetic-Rigid Variant of Huntington Disease in 8 studies
Pyruvic Acid: An intermediate compound in the metabolism of carbohydrates, proteins, and fats. In thiamine deficiency, its oxidation is retarded and it accumulates in the tissues, especially in nervous structures. (From Stedman, 26th ed)
pyruvic acid : A 2-oxo monocarboxylic acid that is the 2-keto derivative of propionic acid. It is a metabolite obtained during glycolysis.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Striatal injection of quinolinic acid (QUIN) resulted in marked inflammation characterized by microgliosis, astrogliosis and enhanced expressions of pro-inflammatory enzymes inducible nitric oxide synthase and cyclooxygenase-2." | 7.73 | Combined minocycline plus pyruvate treatment enhances effects of each agent to inhibit inflammation, oxidative damage, and neuronal loss in an excitotoxic animal model of Huntington's disease. ( Choi, HB; McLarnon, JG; Ryu, JK, 2006) |
| " Striatal injection of quinolinic acid (QUIN) resulted in marked inflammation characterized by microgliosis, astrogliosis and enhanced expressions of pro-inflammatory enzymes inducible nitric oxide synthase and cyclooxygenase-2." | 3.73 | Combined minocycline plus pyruvate treatment enhances effects of each agent to inhibit inflammation, oxidative damage, and neuronal loss in an excitotoxic animal model of Huntington's disease. ( Choi, HB; McLarnon, JG; Ryu, JK, 2006) |
| "Quinolinic acid (QA) has been shown to evoke neurotoxic events via NMDA receptor (NMDAR) overactivation and oxidative stress." | 1.33 | Quinolinic acid modulates the activity of src family kinases in rat striatum: in vivo and in vitro studies. ( Di Stasi, AM; Domenici, MR; Mallozzi, C; Metere, A; Minetti, M; Pèzzola, A; Popoli, P, 2006) |
| " A lower pyruvate concentration of 250 mg/kg was not protective; however, quadruple applications at this dosage was effective in reducing lesion volumes." | 1.32 | Neuroprotective effects of pyruvate in the quinolinic acid rat model of Huntington's disease. ( Kim, SU; McLarnon, JG; Ryu, JK, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gouarné, C | 1 |
| Tardif, G | 1 |
| Tracz, J | 1 |
| Latyszenok, V | 1 |
| Michaud, M | 1 |
| Clemens, LE | 1 |
| Yu-Taeger, L | 1 |
| Nguyen, HP | 1 |
| Bordet, T | 1 |
| Pruss, RM | 1 |
| Jin, YN | 1 |
| Hwang, WY | 1 |
| Jo, C | 1 |
| Johnson, GV | 1 |
| Sheline, CT | 1 |
| Zhu, J | 1 |
| Zhang, W | 1 |
| Shi, C | 1 |
| Cai, AL | 1 |
| Ryu, JK | 3 |
| Kim, SU | 2 |
| McLarnon, JG | 3 |
| Metere, A | 1 |
| Mallozzi, C | 1 |
| Minetti, M | 1 |
| Domenici, MR | 1 |
| Pèzzola, A | 1 |
| Popoli, P | 1 |
| Di Stasi, AM | 1 |
| Choi, HB | 1 |
| Nicoli, F | 1 |
| Vion-Dury, J | 1 |
| Maloteaux, JM | 1 |
| Delwaide, C | 1 |
| Confort-Gouny, S | 1 |
| Sciaky, M | 1 |
| Cozzone, PJ | 1 |
8 other studies available for pyruvic acid and Akinetic-Rigid Variant of Huntington Disease
| Article | Year |
|---|---|
Early deficits in glycolysis are specific to striatal neurons from a rat model of huntington disease.
Topics: Animals; Cell Respiration; Corpus Striatum; Disease Models, Animal; Extracellular Space; Glucose; Gl | 2013 |
Metabolic state determines sensitivity to cellular stress in Huntington disease: normalization by activation of PPARγ.
Topics: Anilides; Animals; Blotting, Western; Cell Line; Cells, Cultured; Glucose; Huntington Disease; Hydro | 2012 |
Mitochondrial inhibitor models of Huntington's disease and Parkinson's disease induce zinc accumulation and are attenuated by inhibition of zinc neurotoxicity in vitro or in vivo.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Carrier Proteins; Cation Transport Proteins; | 2013 |
Neuroprotective effects of pyruvate in the quinolinic acid rat model of Huntington's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administrat | 2003 |
Blockade of quinolinic acid-induced neurotoxicity by pyruvate is associated with inhibition of glial activation in a model of Huntington's disease.
Topics: Animals; Disease Models, Animal; Drug Administration Routes; Enzyme Inhibitors; Guanidines; Huntingt | 2004 |
Quinolinic acid modulates the activity of src family kinases in rat striatum: in vivo and in vitro studies.
Topics: Animals; Corpus Striatum; CSK Tyrosine-Protein Kinase; Dose-Response Relationship, Drug; Down-Regula | 2006 |
Combined minocycline plus pyruvate treatment enhances effects of each agent to inhibit inflammation, oxidative damage, and neuronal loss in an excitotoxic animal model of Huntington's disease.
Topics: Analysis of Variance; Animals; Blotting, Western; Cell Death; Cyclooxygenase 2; Disease Models, Anim | 2006 |
CSF and serum metabolic profile of patients with Huntington's chorea: a study by high resolution proton NMR spectroscopy and HPLC.
Topics: Amino Acids; Chromatography, High Pressure Liquid; Humans; Huntington Disease; Magnetic Resonance Sp | 1993 |